Guy's And ST Thomas' NHS Foundation Trust

New studies presented at the American Thoracic Society Conference validate Brainomix's FDA-cleared e-Lung technology as a reliable tool for identifying progressive pulmonary fibrosis with greater sensitivity than conventional methods.

A groundbreaking UK trial has developed a highly sensitive bone marrow test that can detect returning Acute Myeloid Leukemia up to three months earlier than standard blood tests, potentially doubling survival rates for some patients.

A meta-analysis of 23 publications involving 2,198 patients demonstrated that JAK inhibitors significantly reduce thromboembolic events by 48% in myeloproliferative neoplasm patients, with ruxolitinib showing a 59% reduction in polycythemia vera and myelofibrosis.

Phase 2 PEACOCC trial demonstrates pembrolizumab's efficacy with 42% disease control rate at 12 weeks in previously treated advanced clear cell gynecologic cancer patients.

Avapritinib, a novel drug, has been approved for treating advanced systemic mastocytosis (ASM) by the UK's NICE.